A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of ...

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's ...

Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.

[2] In 1998 only one drug in this class was available, a monoclonal antibody (abciximab) directed against the fibrinogen receptor on the platelet surface GP IIb/IIIa. A more recently approved drug ...

“Platelet transfusions are not particularly ... three from the surgery group and two from the major bleeding group — had drug-related adverse events, but there were no serious drug-related ...

Class, Polyphosphate (polyP)-Based Therapy, Show Promise in Bypassing P2Y12 Inhibition to Restore Normal Clotting Function ...

While routine treatment with aspirin plus a second anti-clotting drug, known as dual antiplatelet therapy (DAPT), can prevent blood clots, these drugs may increase risk for bleeding, especially ...